Immutep Receives Nasdaq Notice of Bid Price Deficiency
Immutep (NASDAQ: IMMP) received a Nasdaq notice that its American Depositary Shares failed to meet the US$1.00 minimum bid price under Nasdaq Listing Rule 5450(a)(1) for the 30 consecutive business days ended April 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immutep (NASDAQ: IMMP) received a Nasdaq notice that its American Depositary Shares failed to meet the US$1.00 minimum bid price under Nasdaq Listing Rule 5450(a)(1) for the 30 consecutive business days ended April 24, 2026.
Nasdaq has given an initial 180-calendar-day compliance period through October 26, 2026, during which Immutep must achieve a closing ADS bid of at least US$1.00 for ten consecutive business days to regain compliance. Trading and the company’s ASX listing remain unaffected. The company will monitor the ADS price and consider options but stated there is no assurance it will regain compliance.
Positive
- Granted a 180-day Nasdaq compliance period ending 26 October 2026
- ADS trading continues; no immediate suspension or delisting action
- Ordinary shares remain listed and trade on ASX without impact
Negative
- Closing bid below US$1.00 for 30 consecutive business days
- Must meet US$1.00 bid for ten consecutive business days to regain compliance
- No assurance the company will regain Nasdaq compliance within period
Details
News Market Reaction – IMMP
On Apr 30, the day this news came out, IMMP closed 3.20% below the previous close.
Data tracked by StockTitan Argus for the Apr 30 session.
Key Figures
- Nasdaq minimum bid price
- US$1.00 per share
- Nasdaq Listing Rule 5450(a)(1) requirement
- Non-compliance period
- 30 consecutive business days
- Period of sub-US$1.00 closing bid before notice
- Initial compliance window
- 180 calendar days
- Time allowed to regain Nasdaq bid price compliance
- Regain-compliance threshold
- US$1.00 per share for 10 days
- Minimum closing bid for at least ten consecutive business days
- Current price
- US$0.4776
- Pre-notice trading level on Nasdaq
- Price vs 52-week high
- -86.47%
- Relative to 52-week high of US$3.5299
- Price vs 52-week low
- 63.11%
- Above 52-week low of US$0.2928
- Market cap
- US$71,829,177
- Equity value before Nasdaq deficiency notice
Historical Context
-
ASCO 2026 abstract acceptance for eftilagimod alfa poster presentation.
-
FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma.
-
Successful SAD completion for IMP761 Phase I with no dose-limiting toxicities.
-
TACTI-004 Phase III NSCLC trial discontinued after futility analysis.
-
TACTI-004 Phase III reached 50% enrolment with 378 patients enrolled.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5450(a)(1) regulatory
minimum bid price requirement regulatory
compliance period regulatory
continuous disclosure obligations regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement.
Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US
The notification has no immediate effect on the listing or trading of the Company’s American Depositary Shares on Nasdaq. In accordance with Nasdaq rules, the Company has been provided an initial compliance period of 180 calendar days, expiring on 26 October 2026, to regain compliance.
If at any time during the compliance period the closing bid price of the Company’s American Depositary Shares is at least US
The Company intends to monitor the bid price of its American Depositary Shares and will consider available options to regain compliance within the prescribed timeframe. There can be no assurance that the Company will regain compliance during this period.
The Company remains listed on the ASX, and this notification does not affect the trading of its ordinary shares on ASX.
Immutep will keep the market informed of any material developments in accordance with its continuous disclosure obligations.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Investors/Media:
Matthew Beck, astr partners
Ph: +1 (917) 415-1750; matthew.beck@astrpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.